Renin‐angiotensin‐aldosterone system blockade in atrial fibrillation and left atrial remodelling

glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS35). Lancet 1998; 352: 837–53. 6 American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009; 32 (Suppl. 1): S13–61. 7 Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343– 50. 8 Knowler WC, Barret-Connor E, Fowler ST et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403. 9 Sjöström L, Lindroos A-K, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683–93. 10 Torgerson JS, Hauptman J, Bodrin MN, Sjöström L. Xenical in the prevention of diabetes in changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–61. 11 Ringborg A, Cropet C, Jönsson B, Lindgren P. Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the international diabetes management practices study. Int J Clin Pract 2009; 63: 997–1007. 12 Hoey H, Aanstoot H-J, Chiarelli F et al., Hvidore Study Group on Childhood Diabetes. Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes. Diabetes Care 2001; 24: 1923–8. 13 Yach D, Stuckler D, Brownell DK. Epidemiologic and economic consequences of the global epidemic of obesity and diabetes. Nat Med 2006; 12: 62–6.

[1]  D. Erdoğan,et al.  The effect of pretreatment with renin‐angiotensin‐aldosterone system blockers on cardioversion success and acute recurrence of atrial fibrillation , 2009, International journal of clinical practice.

[2]  A. Tveit,et al.  Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. , 2007, The American journal of cardiology.

[3]  S. Mohiuddin,et al.  Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. , 2006, American heart journal.

[4]  D. Katritsis.  Is atrial fibrillation an inflammatory disorder? , 2006, European heart journal.

[5]  L. Lai,et al.  Left atrial dysfunction in patients with atrial fibrillation after successful rhythm control for > 3 months. , 2005, Chest.

[6]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[7]  M. Nieminen,et al.  Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[8]  Y. Kagaya,et al.  Expression of the von Willebrand factor in atrial endocardium is increased in atrial fibrillation depending on the extent of structural remodeling. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[9]  M. Lehto,et al.  Persistent atrial fibrillation: a population based study of patients with their first cardioversion. , 2003, International journal of cardiology.

[10]  Wen-Chung Yu,et al.  Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. , 2003, European heart journal.

[11]  T. Nozawa,et al.  Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter. , 2003, Chest.

[12]  J. Egido,et al.  Inflammation and angiotensin II. , 2003, The international journal of biochemistry & cell biology.

[13]  G. Lip,et al.  Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1? , 2003, Stroke.

[14]  E. Bernal,et al.  Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study , 2002, Circulation.

[15]  Z. Yiğit,et al.  Predictors for Maintenance of Sinus Rhythm after Cardioversion in Patients with Nonvalvular Atrial Fibrillation , 2002, Echocardiography.

[16]  A. Maggioni,et al.  Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data , 2001, Heart.

[17]  J B Seward,et al.  Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. , 2001, Mayo Clinic proceedings.

[18]  A. Goette,et al.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. , 2000, Journal of the American College of Cardiology.

[19]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[20]  F. Marín,et al.  Hypofibrinolysis in atrial fibrillation. , 1998, American heart journal.

[21]  T. Oki,et al.  Relationship between flow dynamics in the left atrium and hemostatic abnormalities in patients with nonvalvular atrial fibrillation. , 1998, Japanese heart journal.

[22]  K. Berkin,et al.  Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. , 1997, Heart.

[23]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[24]  H. Crijns,et al.  Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. , 1991, The American journal of cardiology.

[25]  A. Weyman,et al.  Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. , 1990, Circulation.

[26]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[27]  S. Laurent,et al.  Arterial stiffness is associated with left atrial size in hypertensive patients. , 2008, Archives of cardiovascular diseases.

[28]  A. Waldo.  Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2006 .

[29]  James B Seward,et al.  Risks for atrial fibrillation and congestive heart failure in patients >/=65 years of age with abnormal left ventricular diastolic relaxation. , 2004, The American journal of cardiology.